Vaginal Product Formulation Alters the Innate Antiviral Activity and Glycome of Cervicovaginal Fluids with Implications for Viral Susceptibility

Sujeethraj Koppolu, Linlin Wang, Ayushi Mathur, Jayeshwar A. Nigam, Charlene S. Dezzutti, Charles Isaacs, Leslie Meyn, Katherine E. Bunge, Bernard J. Moncla, Sharon L. Hillier, Lisa C. Rohan, Lara Mahal

Research output: Contribution to journalArticle

Abstract

Glycosylated proteins (i.e., mucins, IgG) are important mediators of innate antiviral immunity in the vagina; however, our current knowledge of the role that glycan themselves play in genital immunity is relatively low. Herein, we evaluate the relationship between innate antiviral immunity and glycomic composition in cervicovaginal lavage fluid (CVL) collected as part of a Phase I clinical trial testing the impact of two distinct formulations of the antiretroviral drug dapivirine. Using lectin microarray technology, we discovered that formulation (hydrogel- versus film-based delivery) impacted the CVL glycome, with hydrogel formulations inducing more changes, including a loss of high-mannose. The loss of this epitope correlated to a loss of anti-HIV-1 activity. Glycoproteomic identification of high-mannose proteins revealed a cohort of antiproteases shown to be important in HIV-1 resistance, whose expression covaried with the high-mannose signature. Our data strongly suggests high-mannose as a marker for secreted proteins mediating innate antiviral immunity in vaginal fluids and that drug formulation may impact this activity as reflected in the glycome.

Original languageEnglish (US)
JournalACS Infectious Diseases
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Mannose
Antiviral Agents
Innate Immunity
Drug Compounding
Therapeutic Irrigation
HIV-1
Glycomics
Clinical Trials, Phase I
Proteins
Hydrogel
Vagina
Mucins
Protease Inhibitors
Lectins
Polysaccharides
Epitopes
Immunity
Immunoglobulin G
Technology

Keywords

  • antiproteases
  • antiviral activity
  • cervicovaginal lavage
  • high-mannose
  • innate antiviral immunity
  • lectin microarray

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Vaginal Product Formulation Alters the Innate Antiviral Activity and Glycome of Cervicovaginal Fluids with Implications for Viral Susceptibility. / Koppolu, Sujeethraj; Wang, Linlin; Mathur, Ayushi; Nigam, Jayeshwar A.; Dezzutti, Charlene S.; Isaacs, Charles; Meyn, Leslie; Bunge, Katherine E.; Moncla, Bernard J.; Hillier, Sharon L.; Rohan, Lisa C.; Mahal, Lara.

In: ACS Infectious Diseases, 01.01.2018.

Research output: Contribution to journalArticle

Koppolu, Sujeethraj ; Wang, Linlin ; Mathur, Ayushi ; Nigam, Jayeshwar A. ; Dezzutti, Charlene S. ; Isaacs, Charles ; Meyn, Leslie ; Bunge, Katherine E. ; Moncla, Bernard J. ; Hillier, Sharon L. ; Rohan, Lisa C. ; Mahal, Lara. / Vaginal Product Formulation Alters the Innate Antiviral Activity and Glycome of Cervicovaginal Fluids with Implications for Viral Susceptibility. In: ACS Infectious Diseases. 2018.
@article{0b81a68ea5f6460a93bbbab81d1ab653,
title = "Vaginal Product Formulation Alters the Innate Antiviral Activity and Glycome of Cervicovaginal Fluids with Implications for Viral Susceptibility",
abstract = "Glycosylated proteins (i.e., mucins, IgG) are important mediators of innate antiviral immunity in the vagina; however, our current knowledge of the role that glycan themselves play in genital immunity is relatively low. Herein, we evaluate the relationship between innate antiviral immunity and glycomic composition in cervicovaginal lavage fluid (CVL) collected as part of a Phase I clinical trial testing the impact of two distinct formulations of the antiretroviral drug dapivirine. Using lectin microarray technology, we discovered that formulation (hydrogel- versus film-based delivery) impacted the CVL glycome, with hydrogel formulations inducing more changes, including a loss of high-mannose. The loss of this epitope correlated to a loss of anti-HIV-1 activity. Glycoproteomic identification of high-mannose proteins revealed a cohort of antiproteases shown to be important in HIV-1 resistance, whose expression covaried with the high-mannose signature. Our data strongly suggests high-mannose as a marker for secreted proteins mediating innate antiviral immunity in vaginal fluids and that drug formulation may impact this activity as reflected in the glycome.",
keywords = "antiproteases, antiviral activity, cervicovaginal lavage, high-mannose, innate antiviral immunity, lectin microarray",
author = "Sujeethraj Koppolu and Linlin Wang and Ayushi Mathur and Nigam, {Jayeshwar A.} and Dezzutti, {Charlene S.} and Charles Isaacs and Leslie Meyn and Bunge, {Katherine E.} and Moncla, {Bernard J.} and Hillier, {Sharon L.} and Rohan, {Lisa C.} and Lara Mahal",
year = "2018",
month = "1",
day = "1",
doi = "10.1021/acsinfecdis.8b00157",
language = "English (US)",
journal = "ACS Infectious Diseases",
issn = "2373-8227",
publisher = "American Chemical Society",

}

TY - JOUR

T1 - Vaginal Product Formulation Alters the Innate Antiviral Activity and Glycome of Cervicovaginal Fluids with Implications for Viral Susceptibility

AU - Koppolu, Sujeethraj

AU - Wang, Linlin

AU - Mathur, Ayushi

AU - Nigam, Jayeshwar A.

AU - Dezzutti, Charlene S.

AU - Isaacs, Charles

AU - Meyn, Leslie

AU - Bunge, Katherine E.

AU - Moncla, Bernard J.

AU - Hillier, Sharon L.

AU - Rohan, Lisa C.

AU - Mahal, Lara

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Glycosylated proteins (i.e., mucins, IgG) are important mediators of innate antiviral immunity in the vagina; however, our current knowledge of the role that glycan themselves play in genital immunity is relatively low. Herein, we evaluate the relationship between innate antiviral immunity and glycomic composition in cervicovaginal lavage fluid (CVL) collected as part of a Phase I clinical trial testing the impact of two distinct formulations of the antiretroviral drug dapivirine. Using lectin microarray technology, we discovered that formulation (hydrogel- versus film-based delivery) impacted the CVL glycome, with hydrogel formulations inducing more changes, including a loss of high-mannose. The loss of this epitope correlated to a loss of anti-HIV-1 activity. Glycoproteomic identification of high-mannose proteins revealed a cohort of antiproteases shown to be important in HIV-1 resistance, whose expression covaried with the high-mannose signature. Our data strongly suggests high-mannose as a marker for secreted proteins mediating innate antiviral immunity in vaginal fluids and that drug formulation may impact this activity as reflected in the glycome.

AB - Glycosylated proteins (i.e., mucins, IgG) are important mediators of innate antiviral immunity in the vagina; however, our current knowledge of the role that glycan themselves play in genital immunity is relatively low. Herein, we evaluate the relationship between innate antiviral immunity and glycomic composition in cervicovaginal lavage fluid (CVL) collected as part of a Phase I clinical trial testing the impact of two distinct formulations of the antiretroviral drug dapivirine. Using lectin microarray technology, we discovered that formulation (hydrogel- versus film-based delivery) impacted the CVL glycome, with hydrogel formulations inducing more changes, including a loss of high-mannose. The loss of this epitope correlated to a loss of anti-HIV-1 activity. Glycoproteomic identification of high-mannose proteins revealed a cohort of antiproteases shown to be important in HIV-1 resistance, whose expression covaried with the high-mannose signature. Our data strongly suggests high-mannose as a marker for secreted proteins mediating innate antiviral immunity in vaginal fluids and that drug formulation may impact this activity as reflected in the glycome.

KW - antiproteases

KW - antiviral activity

KW - cervicovaginal lavage

KW - high-mannose

KW - innate antiviral immunity

KW - lectin microarray

UR - http://www.scopus.com/inward/record.url?scp=85053892842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053892842&partnerID=8YFLogxK

U2 - 10.1021/acsinfecdis.8b00157

DO - 10.1021/acsinfecdis.8b00157

M3 - Article

JO - ACS Infectious Diseases

JF - ACS Infectious Diseases

SN - 2373-8227

ER -